Herbal cocktail as anti-infective: Promising therapeutic for the treatment of viral diseases

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 2, 2012, Pages 123-132

  Marathe, Sandhya A ^a   Datey, Akshay A ^a   Chakravortty, Dipshikha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Catechins; Curcumin; Plasmodium; Virus

Indexed keywords

ACICLOVIR; ANTIINFLAMMATORY AGENT; ARTEMISININ; CATECHIN; CHLOROQUINE; CONTRACEPTIVE AGENT; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; EPIGALLOCATECHIN GALLATE; FAMCICLOVIR; GINGER EXTRACT; GREEN TEA EXTRACT; HELIOXANTHIN; HERBACEOUS AGENT; MICROBICIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OSELTAMIVIR; PENCICLOVIR; QR 435; RNA DIRECTED DNA POLYMERASE INHIBITOR; TURMERIC; UNCLASSIFIED DRUG; ZANAMIVIR;

2009 H1N1 INFLUENZA; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CHEMICAL COMPOSITION; COMMON COLD; CONSTIPATION; CURCUMA LONGA; CYTOPATHOGENIC EFFECT; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG TOXICITY; DYSPEPSIA; FEVER; GINGER; HELICOBACTER INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; LONG TERMINAL REPEAT; MALARIA; MENSTRUATION DISORDER; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHINOVIRUS INFECTION; SEXUAL TRANSMISSION; SIDE EFFECT; SINUSITIS; SKIN DISEASE; SORE THROAT; SPRAIN; STOMACH PAIN; SWELLING; TEA; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS REPLICATION; VOMITING;

ANTI-INFECTIVE AGENTS; CURCUMA; FLAVONOIDS; HUMANS; PLANT PREPARATIONS; TEA; VIRUS DISEASES;

EID: 84863952607     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112801619692     Document Type: Review

References (132)

1. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008 Nov 18;6(11): e280.
2. Antunes LC, Finlay BB. A comparative analysis of the effect of antibiotic treatment and enteric infection on intestinal homeostasis. Gut Microbes 2011; 2(2):105-8.
3. Rosenbloom RA, inventor The Quigley Corporation, assignee. Anti-microbial compositions and methods of using same. US7405046 (2008).
4. Marathe SA, Dasgupta I, Gnanadhas DP, Chakravortty D. Multifaceted roles of curcumin: Two sides of a coin! Expert Opin Biol Ther 2011; 11(11): 1485-99.
5. Ch Yiannakopoulou E. Recent patents on antibacterial, antifungal and antiviral properties of tea. Recent Pat Antiinfect Drug Discov 2012; 7(1): 60-5.
6. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7(7): 1894-900.
7. Tayyem RF, Heath DD, Al-Delaimy WK, Rock CL. Curcumin content of turmeric and curry powders. Nutr Cancer 2006; 55(2):126-31.
8. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. Adv Experiment Medicine Biol 2007; 595:1-75.
9. Kim MK, Choi GJ, Lee HS. Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agricultural Food Chemis 2003; 51(6):1578-81.
10. Lee HS. Antiplatelet property of Curcuma longa L. rhizomederived ar-turmerone. Bioresour Technol 2006; 97(12): 1372-6.
11. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2001; 39(6): 541-7.
12. Huang MT, Lou YR, Xie JG, Ma W, Lu YP, Yen P, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19(9):1697-700.
13. Sreejayan, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol. 1997; 49(1):105-7.
14. Syu WJ, Shen CC, Don MJ, Ou JC, Lee GH, Sun CM. Cytotoxicity of curcuminoids and some novel compounds from Curcuma zedoaria. J Nat Prod 1998; 61(12):1531-4.
15. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011; 25(4):1198-207.
16. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemic Pharmacol 2011; 82(12):1807-21.
17. Paterson I, Anderson EA. Chemistry. The renaissance of natural products as drug candidates. Science 2005; 310(5747): 451-3.
18. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66(5): 2500-5.
19. Higdon JV, Frei B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43(1): 89-143.
20. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008; 13:440-52.
21. Sasidharan I, Venugopal VV, Menon AN. Essential oil composition of two unique ginger (Zingiber officinale Roscoe) cultivars from Sikkim. Nat Prod Res 2011 Oct 10.
22. Smith-Palmer A, Stewart J, Fyfe L. Antimicrobial properties of plant essential oils and essences against five important food-borne pathogens. Lett Appl Microbiol 1998; 26(2): 118-22.
23. Janeway CA, Jr., Carding S, Jones B, Murray J, Portoles P, Rasmussen R, et al. CD4+ T cells: Specificity and function. Immunol Rev 1988; 101: 39-80.
24. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266(5193): 1981-6.
25. Brown PO, Bowerman B, Varmus HE, Bishop JM. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc Natl Acad Sci USA 1989; 86(8): 2525-9.
26. Martin SJ, Matear PM, Vyakarnam A. HIV-1 infection of human CD4+ T cells in vitro. Differential induction of apoptosis in these cells. J Immunol 1994; 152(1): 330-42.
27. Davis IC, Girard M, Fultz PN. Loss of CD4+ T cells in human immunodeficiency virus type 1-infected chimpanzees is associated with increased lymphocyte apoptosis. J Virol 1998; 72(6): 4623-32.
28. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, Pahwa S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993; 82(11): 3392-400.
29. Roan NR, Greene WC. A seminal finding for understanding HIV transmission. Cell 2007; 131(6): 1044-6.
30. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-60.
31. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Exp Opin Investig Drugs 2002; 11(8): 1077-97.
32. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med 2000;160(8): 1134-40.
33. Li TS, Tubiana R, Katlama C, Calvez V, Mohand AH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351(9117):1682-6.
34. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 1995; 49(8):1165-70.
35. Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, et al. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem 2005; 48(2): 534-46.
36. Vajragupta O, Boonchoong P, Morris GM, Olson AJ. Active site binding modes of curcumin in HIV-1 protease and integrase. Bioorg Med Chem Lett 2005; 15(14): 3364-8.
37. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1993; 1(6): 415-22.
38. Chun TW, Davey RT, Jr., Engel D, Lane HC, Fauci AS. Reemergence of HIV after stopping therapy. Nature 1999; 401(6756): 874-5.
39. Davey RT, Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96(26): 15109-14.
40. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med 2004; 10(11): 525-31.
41. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 1998; 17(23): 7056-65.
42. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92(4): 451-62.
43. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002; 5(3): 141-51.
44. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 1998; 95(23): 13519-24.
45. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, et al. Curcumin, a novel p300/CREBbinding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279(49): 51163-71.
46. Popov S, Rexach M, Zybarth G, Reiling N, Lee MA, Ratner L, et al. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. EMBO J 1998 Feb 16;17(4): 909-17.
47. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002; 22(9): 2965-73.
48. Zhang HS, Ruan Z, Sang WW. HDAC1/NFkappaB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation. J Cell Physiol 2011; 226(12): 3385-91.
49. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allerg Clin Immunol 2006; 118(6): 1369-74.
50. Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(22): 9033-8.
51. Li S, Hattori T, Kodama EN. Epigallocatechin gallate inhibits the HIV reverse transcription step. Antivir Chem Chemother 2011; 21(6): 239-43.
52. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 2002; 53(1):19-34.
53. Ryan KJ. Sherris Medical Microbiology 4th edition ed: McGraw Hill; 2004.
54. Barton S, Celum C, Shacker TW. The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic. Herpes 2005; 12(1):15-22.
55. Jones C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin Microbiol Rev 2003; 16(1): 79-95.
56. Mitchell BM, Bloom DC, Cohrs RJ, Gilden DH, Kennedy PG. Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J Neurovirol 2003; 9(2): 194-204.
57. Perng GC, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science 2000; 287(5457): 1500-3.
58. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: Biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011; 2011: 1-10.
59. Griffiths A. Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance. Drug Resist Updat 2011; 14(6): 251-9.
60. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5(2): 88-114.
61. Johnston C, Koelle DM, Wald A. HSV-2: In pursuit of a vaccine. J Clin Invest 2011; 121(12): 4600-9.
62. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20(1): 73-83.
63. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a metaanalysis. J Infect Dis 2002; 185(1): 45-52.
64. Burke TR, Jr., Fesen MR, Mazumder A, Wang J, Carothers AM, Grunberger D, et al. Hydroxylated aromatic inhibitors of HIV-1 integrase. J Medicinal Chem 1995; 38(21): 4171-8.
65. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(5): 1839-42.
66. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochemic Pharmacol 1995; 49(8): 1165-70.
67. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorganic Medicinal Chem 1993; 1(6): 415-22.
68. Rosenbloom, R.A., The quigley corporation, assignee. compositions and methods for treatment of herpes. US7175987B2 (2007).
69. Bourne KZ, Bourne N, Reising SF, Stanberry LR. Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res 1999; 42(3): 219-26.
70. Imbalzano AN, Coen DM, DeLuca NA. Herpes simplex virus transactivator ICP4 operationally substitutes for the cellular transcription factor Sp1 for efficient expression of the viral thymidine kinase gene. J Virol 1991; 65(2): 565-74.
71. Pinnoji RC, Bedadala GR, George B, Holland TC, Hill JM, Hsia SC. Repressor element-1 silencing transcription factor/neuronal restrictive silencer factor (REST/NRSF) can regulate HSV-1 immediate-early transcription via histone modification. Virol J 2007; 4: 56.
72. Danaher RJ, Jacob RJ, Steiner MR, Allen WR, Hill JM, Miller CS. Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript-independent manner in neuronal cells. J Neurovirol 2005; 11(3): 306-17.
73. Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology [Research Support, Non-U.S. Gov't] 2008; 373(2): 239-47.
74. Cheng HY, Lin CC, Lin TC. Antiviral properties of prodelphinidin B-2 3'-O-gallate from green tea leaf. Antivir Chem Chemother 2002; 13(4): 223-9.
75. Isaacs CE, Wen GY, Xu W, Jia JH, Rohan L, Corbo C, et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemotherap 2008; 52(3): 962-70.
76. Yang DK, Oh YI, Kim HR, Lee YJ, Moon OK, Yoon H, et al. Serosurveillance for Japanese encephalitis virus in wild birds captured in Korea. J Vet Sci 2011; 12(4): 373-7.
77. Unni SK, Ruzek D, Chhatbar C, Mishra R, Johri MK, Singh SK. Japanese encephalitis virus: from genome to infectome. Microbes Infect 2011; 13(4): 312-21.
78. Chen CJ, Raung SL, Kuo MD, Wang YM. Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol 2002; 83(Pt 8):1897-905.
79. Yeo, H., Austin, D.J., Li, L., Cheng, Y.-C. Y. Novel antiviral helioxanthin analogs. US20080167353 (2008).
80. Cheng, Y.-C., Chou. C.-K., Fu, L., Kuo, Y.-H., Yeh, S.-F., Zhu, J., Mu, V.N.Y.N.T.U. G. H. Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs. US6306899 (2001).
81. Yeo, H., Austin, D.J., Li, L., Cheng, Y.-C. Antiviral helioxanthin analogs. US7754718 (2010).
82. Taylor GM, Hanson PI, Kielian M. Ubiquitin depletion and dominant-negative VPS4 inhibit rhabdovirus budding without affecting alphavirus budding. J Virol 2007; 81(24):13631-9.
83. Yu GY, Lai MM. The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry. J Virol 2005; 79(1): 644-8.
84. Si X, Gao G, Wong J, Wang Y, Zhang J, Luo H. Ubiquitination is required for effective replication of coxsackievirus B3. PLoS One 2008; 3(7): e2585.
85. Dutta K, Ghosh D, Basu A. Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitinproteasome system. J Neuroimmune Pharmacol 2009; 4(3): 328-37.
86. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biologic Chem [Research Support, Non-U.S. Gov't] 2004; 279(12): 11680-5.
87. King JC, Jr., Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006; 355(24): 2523-32.
88. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008; 26 (Suppl 4): D17-22.
89. Cawley J, Hull HF, Rousculp MD. Strategies for implementing school-located influenza vaccination of children: A systematic literature review. J Sch Health 2010; 80(4):167-75.
90. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: Systematic review and meta-analysis of randomised controlled trials. BMJ 2009; 339: b3172.
91. Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007; 119(4): 852-60.
92. Bell DM. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006; 12(1):81-7.
93. Bell DM. Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerg Infect Dis 2006; 12(1): 88-94.
94. Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: Systematic review. BMJ 2009; 339: b3675.
95. Aledort JE, Lurie N, Wasserman J, Bozzette SA. Non-pharmaceutical public health interventions for pandemic influenza: An evaluation of the evidence base. BMC Public Health 2007; 7: 208.
96. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341(18): 1336-43.
97. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010(2): CD001265.
98. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37(6): 471-84.
99. Moscona A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med 2005; 353(25): 2633-6.
100. Chen D-Y, Shien J-H, Tiley L, Chiou S-S, Wang S-Y, Chang T-J, et al. Curcumin inhibits influenza virus infection and haemagglutination activity. Food Chem 2010; 119(4):1346-51.
101. Jariwalla RJ, Roomi MW, Gangapurkar B, Kalinovsky T, Niedzwiecki A, Rath M. Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids. Biofactors 2007; 31(1):1-15.
102. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 2005; 68(2): 66-74.
103. Oxford JS, Lambkin R, Guralnik M, Rosenbloom RA, Petteruti MP, Digian K, et al. In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection. Amer J Therapeut 2007; 14(5): 462-8.
104. Oxford JS, Lambkin R, Guralnik M, Rosenbloom RA, Petteruti MP, Digian K, et al. Preclinical in vitro activity of QR-435 against influenza A virus as a virucide and in paper masks for prevention of viral transmission. Amer J Therapeut 2007; 14(5): 455-61.
105. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415(6872): 673-9.
106. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32(13): 1655-60.
107. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem 1999; 274(27): 19383-8.
108. Sullivan DJ, Jr., Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(21): 11865-70.
109. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Therapeut 1993; 57(2-3): 203-35.
110. Nandakumar DN, Nagaraj VA, Vathsala PG, Rangarajan P, Padmanaban G. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemotherap 2006; 50(5): 1859-60.
111. Govindarajan, P., Pundi, N.R., Vathsala, P.G., Dalavaikodihalli, N.N., Nagaraj, V.A. Antimalarial drug containing synergistic combination of curcumin and artemisinin. Patent US7776911 (2010).
112. Ralph SA, Scherf A. The epigenetic control of antigenic variation in Plasmodium falciparum. Curr Opin Microbiol 2005; 8(4): 434-40.
113. Cui L, Miao J. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: Inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemotherap 2007; 51(2): 488-94.
114. Singh N, Misra K. Computational screening of molecular targets in Plasmodium for novel non resistant anti-malarial drugs. Bioinformation 2009; 3(6): 255-62.
115. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424(6951): 957-61.
116. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14(14): 4491-9.
117. Wang P, Heber D, Henning SM. Quercetin increased bioavailability and decreased methylation of green tea polyphenols in vitro and in vivo. Food Funct 2012.
118. Guo FF, Zou LL, Wu YS, Hu ZM, Li JL, Lv JX, et al. [Preparation and characterization of reference samples of Mycobacterium tuberculosis culture filtrate protein-10 for time-resolved fluoroimmunoassay]. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31(6): 955-9.
119. Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y, Gupta KC. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol 2011; 7(1): 202.
120. Sun LM, Zhang CL, Li P. Characterization, antimicrobial activity, and mechanism of a high-performance (-)-epigallocatechin-3-gallate (EGCG)-CuII/polyvinyl alcohol (PVA) nanofibrous membrane. J Agricult Food Chem 2011; 59(9): 5087-92.
121. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009; 69(5): 1712-6.
122. Ghosh D, Choudhury ST, Ghosh S, Mandal AK, Sarkar S, Ghosh A, et al. Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact 2012; 195(3): 206-14.
123. Michel D, Chitanda JM, Balogh R, Yang P, Singh J, Das U, et al. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma. Eur J Pharmaceut Biopharmaceut 2012.
124. Kundu P, Mohanty C, Sahoo SK. Antiglioma activity of curcuminloaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy. Acta biomaterialia 2012.
125. Fu N, Zhou Z, Jones TB, Tan TT, Wu WD, Lin SX, et al. Production of monodisperse epigallocatechin gallate (EGCG) microparticles by spray drying for high antioxidant activity retention. Int J Pharm 2011; 413(1-2): 155-66.
126. Kim TH, Jiang HH, Youn YS, Park CW, Tak KK, Lee S, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011; 403(1-2): 285-91.
127. Sanna V, Pintus G, Roggio AM, Punzoni S, Posadino AM, Arca A, et al. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem 2011; 54(5): 1321-32.
128. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ. A new role for tamoxifen in oestrogen receptornegative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 2008; 99(7): 1056-63.
129. Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther 2010; 9(5): 1396-407.
130. Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012; 18(2): 126-35.
131. Kondo A, Takeda T, Li B, Tsuiji K, Kitamura M, Wong TF, et al. Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis. Int J Clin Oncol 2012.
132. Isacchi B, Bergonzi MC, Grazioso M, Righeschi C, Pietretti A, Severini C, et al. Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice. Eur J Pharmaceut Biopharmaceut. [Research Support, Non-U.S. Gov't] 2012; 80(3): 528-34.